Karyopharm myeloma drug yields mixed data in myelofibrosis trial [Yahoo! Finance]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Yahoo! Finance
Dive Brief: Karyopharm Therapeutics' multiple myeloma drug Xpovio helped people with the blood disorder myelofibrosis on a key measure of health, but didn't help reduce their symptoms when combined with the approved drug Jakafi in a Phase 3 trial, the company said Tuesday The company said it plans to discuss the data with the Food and Drug Administration, aiming to seek an extended approval for Xpovio, its only marketed drug and source of revenue. Approval in myelofibrosis could be “transformative” for Karyopharm by tripling Xpovio revenue, which stood at $115 million in 2025 , RBC Capital Markets analyst Brian Abrahams wrote in a note to clients. Following release of the data, Karyopharm announced it is raising $30 million from a private placement with healthcare investment firm RA Capital. Shares fell as much as 15% in Tuesday morning trading. Dive Insight: Myelofibrosis stems from bone marrow scarring that impedes the body's ability to produce healthy blood cells. Sympto
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics (KPTI) had its price target lowered by Robert W. Baird from $21.00 to $15.00. They now have an "outperform" rating on the stock.MarketBeat
- Karyopharm Therapeutics (KPTI) had its price target lowered by HC Wainwright from $15.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript [Seeking Alpha]Seeking Alpha
- Karyopharm Therapeutics jumps 18%, raises $30M privately [Seeking Alpha]Seeking Alpha
- Karyopharm Announces $30 Million Private Placement with RA Capital [TheStreet.com]TheStreet.com
KPTI
Earnings
- 2/12/26 - Miss
KPTI
Sec Filings
- 3/24/26 - Form 8-K
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- KPTI's page on the SEC website